Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PTC Therapeutics to Host First Deep Dive Webinar on Bio-e Platform

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in...

PTCT : 49.90 (+0.54%)
PTC Therapeutics, Inc. to Hold Virtual 2020 Annual Meeting of Stockholders

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the...

PTCT : 49.90 (+0.54%)
Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

PFE : 38.18 (+2.06%)
SRPT : 153.00 (-2.65%)
PTCT : 49.90 (+0.54%)
SLDB : 3.03 (-3.50%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate of 50,025 shares of its common stock and...

PTCT : 49.90 (+0.54%)
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc.

PTCT : 49.90 (+0.54%)
BSGM : 9.89 (-5.09%)
PTC Therapeutics to Acquire Censa Pharmaceuticals

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development...

PTCT : 49.90 (+0.54%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present in a virtual format at the following conferences:

PTCT : 49.90 (+0.54%)
PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -55.17% and -13.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PTCT : 49.90 (+0.54%)
PTC Therapeutics: 1Q Earnings Snapshot

SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $112.7 million in its first quarter.

PTCT : 49.90 (+0.54%)
PTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending .

PTCT : 49.90 (+0.54%)
Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive results from part 2 of the pivotal FIREFISH study evaluating risdiplam in infants with type 1 spinal muscular atrophy (SMA). The global study...

PTCT : 49.90 (+0.54%)
Earnings Preview: PTC Therapeutics (PTCT) Q1 Earnings Expected to Decline

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTCT : 49.90 (+0.54%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 17, 2020 it approved non-statutory stock options to purchase an aggregate of 151,850 shares of its common stock and 6,260 restricted...

PTCT : 49.90 (+0.54%)
Look for Shares of Ptc Therapeutics to Potentially Pullback after Yesterday's 3.77% Rise

Ptc Therapeutics (NASDAQ:PTCT) traded in a range yesterday that spanned from a low of $48.42 to a high of $51.70. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high...

PTCT : 49.90 (+0.54%)
Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors

ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro's Board of Directors effective immediately. Dr. Klein, Chief Development...

PTCT : 49.90 (+0.54%)
CLPT : 4.19 (+11.44%)
PTC Therapeutics Announces New Leadership Appointments

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Matthew Klein, M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer. Dr. Klein will be responsible for...

PTCT : 49.90 (+0.54%)
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2020 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2020 financial results and provide an update on the company's business...

PTCT : 49.90 (+0.54%)
Roche's NDA for SMA Drug Gets Expanded Review From FDA

The FDA stretches the review timeline of Roche's (RHHBY) NDA for risdiplam by three months, which is being evaluated to treat spinal muscular atrophy. A decision is now pending on Aug 24, 2020.

BIIB : 300.50 (-0.32%)
RHHBY : 43.9500 (+2.00%)
NVS : 86.28 (+2.17%)
PTCT : 49.90 (+0.54%)
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application...

PTCT : 49.90 (+0.54%)
PTC Therapeutics Announces Management Change

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Marcio Souza, Chief Operating Officer, has resigned and will be leaving the company by April 25th, 2020.

PTCT : 49.90 (+0.54%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -2.57 , SEDG -1.95 , THC -0.82 , TER -3.03 , LITE -1.54
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar